What happens to a medical device maker when hospitals keep changing the way they treat breathing patients? For Fisher & Paykel Healthcare (ASX:FPH), the answer so far in 2026 has been a lifted profit outlook and one of the more resilient growth stories among ASX 200 healthcare stocks.

That scale raises a practical question for investors in Australian shares: how could one respiratory care specialist influence momentum in a sector that has at times weighed on the broader benchmark? The answer involves consumables, currency and the market's appetite for dependable Earnings growth.

Humidifiers, Masks and a Consumables Engine

Fisher & Paykel Healthcare designs and manufactures products used in respiratory care, acute care and the treatment of obstructive sleep apnoea. It runs two product groups.

The Hospital group sells humidification systems and the single-use consumables that go with them, used in invasive and non-invasive ventilation, nasal high-flow therapy and surgery. The Homecare group sells masks and humidified devices for people with sleep apnoea, as well as home respiratory products.

The Business model relies heavily on recurring revenue. Once a hospital installs hardware, each patient treated uses new consumables. That is why management keeps pointing to "changing clinical practice", as more clinicians adopt nasal high-flow and humidified therapies outside intensive care.

A FY26 Base

For the year ended 31 March 2026, reported on 26 May, Fisher & Paykel Healthcare delivered (all figures in New Zealand dollars):

  • Operating revenue up 14 per cent to $2.31 billion, or 12 per cent in constant currency
  • Net profit after tax up 24 per cent to $468.5 million
  • Hospital revenue up 18 per cent to $1.51 billion
  • Homecare revenue up 8 per cent to $802.7 million
  • Gross Margin up 80 basis points to 63.7 per cent

A final Dividend of 33.0 cents per share, lifting the full-year dividend 22 per cent to 52.0 cents

The margin gain came despite US tariffs, which the company estimated trimmed gross margin by about 90 basis points in constant currency. Research and Development spending was $235.5 million, around 10 per cent of revenue.

The August Upgrade

The 21 August update, issued ahead of the annual shareholders' meeting, was the latest catalyst. The company guided first-half FY27 revenue (six months to 30 September 2026) of about $1.24 billion and net profit after tax of about $280 million. It said that represents growth of 14 per cent and 24 per cent respectively, with the profit growth figure excluding US Tariff refunds.

Full-year FY27 guidance was raised to:

Revenue of $2.47–$2.57 billion, from $2.45–$2.57 billion

Net profit after tax of $525–$565 million, from $500–$550 million

The profit outlook includes about $23 million of refunds relating to US tariffs imposed under the International Emergency Economic Powers Act (IEEPA), and is based on exchange rates as at 31 July 2026, including NZD:USD of 0.59. Managing director and CEO Lewis Gradon pointed to a "start" in the Hospital product group, citing continued Demand for hardware and consumables growth, alongside improvement programmes that are helping gross margin.

How FPH Feeds Into ASX 200 Momentum

Fisher & Paykel Healthcare's influence on the index runs through three channels.

Growth and quality premium. FPH has typically traded on a higher valuation multiple than the broader market. Upgrades can therefore spark outsized share price moves, while any stumble in guidance can have the opposite effect. That makes the stock a useful read on how much investors are prepared to pay for defensive growth.

Currency and global demand. Most revenue is earned offshore, largely in US dollars and euros, while much of the cost base sits in New Zealand and Mexico. A weaker New Zealand dollar tends to lift reported earnings. For Australian investors, FPH offers exposure to North American and European hospital spending rather than domestic consumer or bank cycles.

Risks on the Radar

FPH's upgrade leaves little room for disappointment. Among the risks to monitor:

  • Trade policy. The outlook assumes current global tariff rates, policies and applications continue. Changes to US tariffs could affect margins.
  • Currency swings. A stronger New Zealand dollar would reduce the value of offshore sales.
  • Respiratory season variability. Hospital demand can fluctuate with the severity of Northern Hemisphere flu and COVID-19 seasons.
  • Homecare competition. The masks market is competitive, and weight-loss drugs such as GLP-1 medicines remain a debated Factor for long-term sleep apnoea demand.
  • Valuation. A premium multiple means expectations are high.

What Investors Could Watch Next

  • The first-half FY27 result, covering the six months to 30 September 2026 and typically reported in November
  • Hospital consumables growth as a gauge of changing clinical practice
  • Any updates on US tariff settings and the timing of refunds
  • NZD:USD movements relative to the 0.59 guidance assumption
  • Commentary on the Northern Hemisphere winter season